OncoBayes progressing OB-001 to tackle ADC resistance and TKI brain penetration

Privately held, clinical-stage pharmaceutical company OncoBayes announced completion of preclinical work on OB-001. The company said the work demonstrated the product’s potential to address ADC resistance and another major unmet need in oncology; the provided article excerpt includes no efficacy figures or clinical data.